| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.73B | 4.31B | 3.26B | 3.85B | 3.25B | 1.96B |
| Gross Profit | 1.48B | 1.33B | 1.14B | 1.37B | 1.28B | 524.14M |
| EBITDA | 662.59M | 570.16M | 366.94M | 387.81M | 467.11M | 432.01M |
| Net Income | 279.13M | 215.28M | 115.89M | 69.31M | 213.40M | 325.79M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 3.80B | 3.77B | 4.01B | 3.84B | 2.64B |
| Cash, Cash Equivalents and Short-Term Investments | 60.40M | 51.52M | 70.63M | 33.50M | 29.59M | 51.84M |
| Total Debt | 0.00 | 470.70M | 877.11M | 1.01B | 933.99M | 350.80M |
| Total Liabilities | -2.28B | 1.53B | 1.68B | 2.03B | 1.90B | 905.20M |
| Stockholders Equity | 2.28B | 2.28B | 2.10B | 1.98B | 1.94B | 1.73B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 310.28M | 194.33M | 79.75M | -480.71M | -150.70M |
| Operating Cash Flow | 0.00 | 380.41M | 383.74M | 298.81M | 506.56M | 322.45M |
| Investing Cash Flow | 0.00 | -66.82M | -100.42M | -205.59M | -984.14M | -396.61M |
| Financing Cash Flow | 0.00 | -297.83M | -271.01M | -99.94M | 461.07M | 30.22M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | ₹1.14B | 10.60 | ― | 10.99% | -76.65% | -76.77% | |
66 Neutral | ₹2.01B | 15.78 | ― | 1.11% | -37.34% | -45.55% | |
63 Neutral | ₹7.87B | 17.11 | ― | 0.38% | 12.35% | 6.79% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
61 Neutral | ₹5.61B | 21.46 | ― | 0.97% | 40.79% | 109.95% | |
57 Neutral | ₹6.01B | 28.38 | ― | ― | 2.76% | 30.68% | |
49 Neutral | ₹1.10B | 990.50 | ― | ― | 574.56% | ― |
DMCC Speciality Chemicals Limited announced the closure of its trading window from January 1, 2026, until 48 hours after the board meeting that will consider the unaudited financial results for the quarter and nine months ending December 31, 2025. This move is in compliance with SEBI’s insider trading regulations and aims to prevent insider trading by designated persons and their immediate relatives during this period.